Patents by Inventor Yoshito Numata
Yoshito Numata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10745491Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: January 11, 2019Date of Patent: August 18, 2020Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Publication number: 20190211114Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: January 11, 2019Publication date: July 11, 2019Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Patent number: 10239955Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: June 2, 2017Date of Patent: March 26, 2019Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Publication number: 20170275378Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: June 2, 2017Publication date: September 28, 2017Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Patent number: 9701757Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: March 12, 2014Date of Patent: July 11, 2017Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Patent number: 9296825Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: October 11, 2012Date of Patent: March 29, 2016Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
-
Publication number: 20160009819Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: March 12, 2014Publication date: January 14, 2016Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Patent number: 9085611Abstract: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.Type: GrantFiled: January 4, 2013Date of Patent: July 21, 2015Assignee: SHIONOGI & CO., LTD.Inventors: Yoshinori Yamano, Yoshito Numata, Takafumi Sato, Toshinaga Tsuji, Keiko Kawamoto
-
Publication number: 20150025225Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: October 11, 2012Publication date: January 22, 2015Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
-
Patent number: 8883977Abstract: An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.Type: GrantFiled: April 28, 2011Date of Patent: November 11, 2014Assignees: Shionogi & Co., Ltd., National University Corporation Hokkaido UniversityInventors: Shin-Ichiro Nishimura, Shoichi Naito, Naoki Ohyabu, Tatsuya Takahashi, Yoshito Numata, Keiko Kawamoto
-
Patent number: 8722856Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.Type: GrantFiled: October 28, 2009Date of Patent: May 13, 2014Assignees: National University Corporation Hokkaido University, Shionogi & Co., Ltd.Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
-
Patent number: 8536313Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: GrantFiled: July 8, 2008Date of Patent: September 17, 2013Assignee: Shionogi & Co., Ltd.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Patent number: 8501179Abstract: Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.Type: GrantFiled: January 8, 2009Date of Patent: August 6, 2013Assignee: Shionogi & Co., Ltd.Inventors: Yoshito Numata, Yoshinori Yamano, Takafumi Sato, Toshinaga Tsuji
-
Publication number: 20130045543Abstract: An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.Type: ApplicationFiled: April 28, 2011Publication date: February 21, 2013Inventors: Shin-Ichiro Nishimura, Shoichi Naito, Naoki Ohyabu, Tatsuya Takahashi, Yoshito Numata
-
Publication number: 20120237948Abstract: The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope.Type: ApplicationFiled: September 16, 2010Publication date: September 20, 2012Applicant: Shionogi & Co., Ltd.Inventors: Yoshito Numata, Akira Yamauchi, Junji Onoda, Shoji Yamane, Tomoko Maeda
-
Publication number: 20120093808Abstract: Provided are a humanized monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient, as an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Concretely, the humanized monoclonal antibody of the present invention has an excellent inhibitory activity on the cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the humanized monoclonal antibody of the present invention has a high affinity for PcrV.Type: ApplicationFiled: March 9, 2010Publication date: April 19, 2012Applicant: Shionogi & Co., Ltd.Inventors: Yoshinori Yamano, Yoshito Numata, Takafumi Sato, Toshinaga Tsuji, Keiko Kawamoto
-
Publication number: 20120040375Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.Type: ApplicationFiled: October 28, 2009Publication date: February 16, 2012Applicants: SHIONOGI & CO., LTD.Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
-
Publication number: 20110150896Abstract: Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.Type: ApplicationFiled: January 8, 2009Publication date: June 23, 2011Applicant: Shionogi & Co., Ltd.Inventors: Yoshito Numata, Yoshinori Yamano, Takafumi Sato, Toshinaga Tsuji
-
Publication number: 20100330092Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: ApplicationFiled: July 8, 2008Publication date: December 30, 2010Applicant: SHIONLGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Publication number: 20090298196Abstract: The present invention is intended to provide a method of rapidly, simply and accurately measuring a recombinant protein. As means for resolution, the protein quantity is measured by causing the expression of a fusion protein with the target protein and epitope tags containing two types of epitopes, bringing them into contact with detection antibodies which specifically recognize each epitope, and detecting a phenomenon caused by both detection antibodies coming close to each other.Type: ApplicationFiled: January 26, 2006Publication date: December 3, 2009Inventors: Ken-ichiro Uwabe, Koji Enomoto, Junji Onoda, Yoshito Numata, Hiroshi Takemoto